Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals


  • Products Id :- GDHC0506MD
  • |
  • Pages: 89
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, December 2016 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, December 2016 12

2.2.1 Lonza to Acquire Capsugel from KKR & Co for USD5.5 Billion 12

2.2.2 Nanjing Hicin Pharma to Raise USD3.19 Billion in IPO of Shares 12

2.2.3 Incyte Enters into Licensing Agreement with Merus 13

2.2.4 Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 14

2.2.5 Novartis Acquires Ziarco Group 15

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, December 2016 16

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, December 2016 17

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 18

3.1 Pharmaceuticals & Healthcare, Global, M&A, December 2016 18

3.1.1 Top M&A Deals in December 2016 19

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, July 2016-December 2016 20

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, December 2016 21

3.2.1 Top Equity Offering Deals in December 2016 22

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, July 2016-December 2016 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, December 2016 24

3.3.1 Top PE/VC Deals in December 2016 25

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, December 2016 26

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, December 2016 27

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, July 2016-December 2016 29

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, July 2016-December 2016 30

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, December 2016 31

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, July 2016-December 2016 33

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), December 2016 34

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, December 2016 35

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 36

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, July 2016-December 2016 38

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), July 2016-December 2016 39

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2016-December 2016 40

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, December 2016 42

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, December 2016 42

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 44

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), July 2016-December 2016 45

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), July 2016-December 2016 46

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), July 2016-December 2016 47

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), July 2016-December 2016 49

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, December 2016 50

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, December 2016 51

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, December 2016 52

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 53

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, December 2016 53

5.1.1 Oncology-Deals of the Month 54

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, December 2016 56

5.2.1 Central Nervous System-Deals of the Month 57

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, December 2016 59

5.3.1 Infectious Diseases-Deals of the Month 60

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, December 2016 62

5.4.1 Cardiovascular-Deal of the Month 63

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, December 2016 65

5.5.1 Immunology-Deals of the Month 66

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, December 2016 68

5.6.1 Gastrointestinal-Deal of the Month 69

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, December 2016 71

5.7.1 Metabolic Disorders-Deal of the Month 72

6 Deal Summary by Geography 74

6.1 Pharmaceuticals & Healthcare, North America Deals, December 2016 74

6.1.1 North America-Deals of the Month 75

6.2 Pharmaceuticals & Healthcare, Europe, Deals, December 2016 77

6.2.1 Europe-Deals of the Month 78

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, December 2016 80

6.3.1 Asia-Pacific-Deals of the Month 81

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, December 2016 82

6.4.1 Rest of the World-Deals of the Month 83

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 85

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, July 2016-December 2016 85

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, July 2016-December 2016 86

8 Further Information 87

8.1 Methodology 87

8.2 About GlobalData 88

8.3 Contact Us 88

8.4 Disclosure information 88

8.5 Disclaimer 89

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), July 2016-December 2016 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), December 2016 16

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), December 2016 17

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), July 2016-December 2016 18

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2016-December 2016 20

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), July 2016-December 2016 21

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2016-December 2016 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), July 2016-December 2016 24

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2016-December 2016 26

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), December 2016 27

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%),December 2016 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2016-December 2016 29

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2016-December 2016 31

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2016-December 2016 33

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 34

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 36

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, July 2016-December 2016 38

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, July 2016-December 2016 39

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2016-December 2016 40

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), July 2016-December 2016 42

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 44

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2016-December 2016 45

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 46

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals,July 2016-December 2016 47

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m),July 2016-December 2016 48

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), December 2016 49

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), July 2016-December 2016 53

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), July 2016-December 2016 56

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), July 2016-December 2016 59

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), July 2016-December 2016 62

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), July 2016-December 2016 65

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 68

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 71

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), July 2016-December 2016 74

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), July 2016-December 2016 77

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), July 2016-December 2016 80

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), July 2016-December 2016 82

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2016-December 2016 85

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2016-December 2016 86

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, December 2016 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), December 2016 17

Table 4:Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 19

Table 5:Pharmaceuticals & Healthcare, Global, Top M&A Deals, December 2016 19

Table 6:Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2016-December 2016 20

Table 7:Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 22

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, December 2016 22

Table 9:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 23

Table 10:Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 25

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, December 2016 25

Table 12:Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, July 2016-December 2016 26

Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number OfDeals and Deal Values (%),December 2016 28

Table 14:Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2016-December 2016 29

Table 15:Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, July 2016-December 2016 30

Table 16:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2016-December 2016 32

Table 17:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2016-December 2016 33

Table 18:Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 34

Table 19:Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 35

Table 20:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 37

Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, July 2016-December 2016 39

Table 22:Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), July 2016-December 2016 41

Table 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 43

Table 24:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), July 2016-December 2016 44

Table 25:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2016-December 2016 45

Table 26:Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), December 2016 46

Table 27:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, July 2016-December 2016 48

Table 28:Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2016 50

Table 29:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, December 2016 50

Table 30:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, December 2016 51

Table 31:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, December 2016 52

Table 32:Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 54

Table 33:Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 57

Table 34:Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 60

Table 35:Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 63

Table 36:Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 66

Table 37:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 69

Table 38:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 72

Table 39:Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 75

Table 40:Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 78

Table 41:Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 81

Table 42:Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), July 2016-December 2016 83

Table 43:Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), July 2016-December 2016 85

Table 44:Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2016-December 2016 86

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 1000 INR 71920
Site License
USD 2000 INR 143840
Corporate User License
USD 3000 INR 215760

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com